Please upgrade your browser.
Two cancer drugs triple the risk of blood clots in the arteries, a meta-analysis published online in the Journal of Clinical Oncology (29 March 2010) has found.
Cancer sufferers in the UK are still failing to get drugs widely available elsewhere in Europe despite government efforts to speed up approvals, the Tories have said.
"It's devastating for us, because three months ago, before Sutent, he was a dying man. Now he is unrecognisable, almost back to normal - it's clearly working for him."
A drug for advanced kidney cancer, Sutent, was recommended as the first treatment for patients in March 2009 after a vigorous campaign by doctors and patients. But three other drugs for the same type of cancer have had their application to be used as a first line treatment turned down by NICE.
Cancer Research UK-funded scientists have identified two genes linked to Wilms tumour a type of childhood kidney cancer - according to research published in Clinical Cancer Research.
The National Institute for Health and Clinical Excellence (NICE) is examining percutaneous radiofrequency ablation of renal cancer and will publish guidance on its safety and efficacy to the NHS in England, Wales, Scotland and Northern Ireland.
Dr. McCormick is a pioneering molecular biologist and cancer researcher, whose contributions include the development of sorafenib, a small-molecule tyrosine protein kinase inhibitor used for the treatment of kidney cancer and advanced liver cancer.
These compelling factors include strong efficacy signals from a wide spectrum of preclinical studies in animal models involving renal cell carcinoma, prostate cancer, neuroblastoma, ovarian cancer, and lung cancer, and now the successful completion of the phase 1 trial announced today that demonstrated an excellent safety profile and produced evidence of pharmacological activity in cancer patients.
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice
Cancer gene/virus therapy will not achieve its potential until vectors can be delivered systemically to metastatic disease.
The use of the oral vascular endothelial growth factor receptor tyrosine kinase inhibitors sunitinib and sorafenib resulted in a threefold increased relative risk for arterial thrombosis, according to the results of a meta-analysis.
|NeonCRM by Neon One|